2024
Opioid prescribing trends and pain scores among adult patients with cancer in a large health system.
Baum L, Soulos P, KC M, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Liberatore M, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Journal Of Clinical Oncology 2024, 42: 11059-11059. DOI: 10.1200/jco.2024.42.16_suppl.11059.Peer-Reviewed Original ResearchDocumented painHealth systemOpioid prescribingOpioid prescriptionsOpioid prescribing trendsYale New Haven Health SystemPrescribing trendsMetastatic cancerDocumented pain scoresUS health systemOpioid usePain scoresAdult patientsCalculated predicted probabilitiesFlowsheet dataRetrospective cohort studyRelated harmSolid tumor malignanciesCohort studyCancer painPrescribingContext of cancer treatmentStudy criteriaPainSurgery cohortSPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman D, Ruddy K, Grzegorczyk V, Kroenke K, Griffin J, Ridgeway J, Chlan L, Tofthagen C, Leventakos K, Strand J, Austin J, Smith A, Mitchell S, Herrin J, Cheville A. SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers. Journal Of Clinical Oncology 2024, 42: 11108-11108. DOI: 10.1200/jco.2024.42.16_suppl.11108.Peer-Reviewed Original ResearchSymptom burdenHigh school educationDiverse sample of patientsAmerican Indian/Alaska Native (AI/ANSymptom management interventionsHigh symptom burdenPhysical function impairmentComposite scoreCancer symptom controlTotal symptom burdenSchool educationComposite mean scoresSymptom interventionMetastatic diseaseMetastatic cancerSymptom prevalenceSample of patientsSymptom surveyEmployment statusDisability statusMean scoreICD codesCancer typesManagement interventionsSymptom controlCurrent management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey.
Odzer N, Pusztai L, Rozenblit M. Current management practices of de novo oligometastatic breast cancer: Real-world data from a physician survey. Journal Of Clinical Oncology 2024, 42: 1104-1104. DOI: 10.1200/jco.2024.42.16_suppl.1104.Peer-Reviewed Original ResearchMultimodal therapySurgical resectionOverall survivalPrimary tumorRandomized trialsResponse to initial chemotherapyTreated with multimodality therapyOligometastatic breast cancerRecommended surgical resectionLocally advanced cancerPalliative systemic chemotherapyProlonged overall survivalTime of diagnosisRandomized clinical trialsOS benefitSystemic chemotherapyInitial chemotherapyResidual lesionsSurvival benefitNCCN GuidelinesReceptor subtypesRetrospective studyTreatment modalitiesMetastatic cancerAblative radiationSurvivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations
Hart N, Nekhlyudov L, Smith T, Yee J, Fitch M, Crawford G, Koczwara B, Ashbury F, Lustberg M, Mollica M, Smith A, Jefford M, Chino F, Zon R, Agar M, Chan R. Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations. Supportive Care In Cancer 2024, 32: 313. PMID: 38679639, PMCID: PMC11056340, DOI: 10.1007/s00520-024-08465-8.Peer-Reviewed Original ResearchConceptsQuality survivorship careSurvivorship carePractice recommendationsUnmet supportive care needsPalliative care frameworkSupportive care needsSystematic reviewModified Delphi consensus processEnd-of-lifeResultsA systematic reviewDelphi consensus processMethodsAn expert panelCancer survivorshipCare goalsCancer careCare experiencesCare needsCare frameworkHealth outcomesASCO membersConsensus processCareDelphi studyExpert panelMetastatic cancerThe impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study
Castellano C, Sun T, Ravindranathan D, Hwang C, Balanchivadze N, Singh S, Griffiths E, Puzanov I, Ruiz‐Garcia E, Vilar‐Compte D, Cárdenas‐Delgado A, McKay R, Nonato T, Ajmera A, Yu P, Nadkarni R, O’Connor T, Berg S, Ma K, Farmakiotis D, Vieira K, Arvanitis P, Saliby R, Labaki C, Zarif T, Wise‐Draper T, Zamulko O, Li N, Bodin B, Accordino M, Ingham M, Joshi M, Polimera H, Fecher L, Friese C, Yoon J, Mavromatis B, Brown J, Russell K, Nanchal R, Singh H, Tachiki L, Moria F, Nagaraj G, Cortez K, Abbasi S, Wulff‐Burchfield E, Puc M, Weissmann L, Bhatt P, Mariano M, Mishra S, Halabi S, Beeghly A, Warner J, French B, Bilen M, Consortium F. The impact of cancer metastases on COVID‐19 outcomes: A COVID‐19 and Cancer Consortium registry‐based retrospective cohort study. Cancer 2024, 130: 2191-2204. PMID: 38376917, PMCID: PMC11141719, DOI: 10.1002/cncr.35247.Peer-Reviewed Original ResearchConceptsSupplemental O<sub>2</sub>COVID-19 severityMetastatic cancerLogistic regression modelsMetastases to other sitesSite of metastatic cancerCOVID-19 outcomesMetastasis to boneRetrospective cohort studyAll-cause mortalityIntensive care unitDay mortalityLymph nodesIncreased hospitalization ratesMechanical ventilationCohort studyMetastasisCare unitPatientsCancer metastasisRegression modelsCancerSevere outcomesCancer ConsortiumOrdinal logistic regression model
2023
Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study
Alamgeer M, Ling R, Ueno R, Sundararajan K, Sundar R, Pilcher D, Subramaniam A. Frailty and long-term survival among patients in Australian intensive care units with metastatic cancer (FRAIL-CANCER study): a retrospective registry-based cohort study. The Lancet Healthy Longevity 2023, 4: e675-e684. PMID: 38042160, DOI: 10.1016/s2666-7568(23)00209-x.Peer-Reviewed Original ResearchConceptsIntensive care unitRegistry-based cohort studyLong-term survivalAustralian intensive care unitsRetrospective registry-based cohort studyMetastatic cancerAssociated with shorter survival timeEffect of frailtyClinical Frailty ScaleShorter survival timeSurvival timeCohort studyAssociated with poor long-term survivalCare unitPoor long-term survivalIntensive care unit admissionTime-limited trialsCandidacy of patientsCox proportional hazards regression modelsRobust sandwich variance estimatorProportion of patientsProportional hazards regression modelsHazards regression modelsImpact of frailtyOverall survivalCore Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer
Coman M, Pusztai L, Hooley R, Andreveja L, Kim L, Joshi N, Bersenev A, Krause D, Park T. Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer. Journal Of Immunotherapy 2023, 47: 49-53. PMID: 37991241, DOI: 10.1097/cji.0000000000000495.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesCore needle biopsyTriple-negative breast cancerNeedle biopsyBreast cancerEx vivoT-cell receptor clonalityUltrasound-guided core needle biopsyTriple negative breast cancer tumorsMorbidity of surgeryAdoptive cell therapyBreast cancer tumorsTIL generationAdoptive transferTIL culturesMultiple lesionsCytokine secretionMetastatic cancerSame patientTumor tissueCell therapyPatientsCancer tumorsCancerSurgeryTrends in new and persistent opioid use in older adults with and without cancer
Baum L, KC M, Soulos P, Jeffery M, Ruddy K, Lerro C, Lee H, Graham D, Rivera D, Leapman M, Jairam V, Dinan M, Gross C, Park H. Trends in new and persistent opioid use in older adults with and without cancer. Journal Of The National Cancer Institute 2023, 116: 316-323. PMID: 37802882, DOI: 10.1093/jnci/djad206.Peer-Reviewed Original ResearchAdditional opioid useNew opioid useOpioid useNon-metastatic cancerPersistent opioid useRetrospective cohort studySolid tumor malignanciesClinical strataEligible patientsNaïve patientsOpioid prescribingMetastatic patientsSurgery patientsCohort studySEER-MedicareMetastatic cancerPatientsTumor malignancyCancerOlder adultsSurgeryRandom sampleAdditional useChemotherapyPrescribingEnd-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. Journal Of Clinical Oncology 2023, 41: 4729-4738. PMID: 37339389, PMCID: PMC10602547, DOI: 10.1200/jco.22.02180.Peer-Reviewed Original ResearchConceptsSystemic treatmentEnd of lifeWhite patientsBlack patientsOdds ratioLarge real-world populationPractice settingsTreatment ratesPatient-level factorsEmergency department useIntensive care unitReal-world populationDay of deathImmunotherapy eraSystemic therapyOncologic treatmentCare unitDeidentified databaseDepartment usePatient raceInsurance typeMetastatic cancerDownstream careMedicaid patientsHigher oddsEpigenetic markers and therapeutic targets for metastasis
Kravitz C, Yan Q, Nguyen D. Epigenetic markers and therapeutic targets for metastasis. Cancer And Metastasis Reviews 2023, 42: 427-443. PMID: 37286865, PMCID: PMC10595046, DOI: 10.1007/s10555-023-10109-y.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsEpigenomic alterationsLineage integrityTherapeutic targetEpigenetic markersCancer cellsGenetic aberrationsCurrent knowledgeHuman tumorsMalignant cell cloneTumor progressionDNANumber of discoveriesCell clonesDisseminated diseaseCertain organsPrimary tumorTherapeutic responseMetastatic cancerEpigenomeChromatinHistonesLiquid biopsyAlterationsClonesTargetChanges in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study
Bergerot C, Philip E, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin Z, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clinical Genitourinary Cancer 2023, 21: 626-630.e3. PMID: 37391301, PMCID: PMC11225089, DOI: 10.1016/j.clgc.2023.05.018.Peer-Reviewed Original ResearchConceptsPerception of cureExpectation of cureGenitourinary cancersImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyImmune checkpoint inhibitorsProportion of patientsSevere side effectsLongitudinal studyChi-square testICI therapyCheckpoint inhibitorsInhibitor therapyECOG scoreGeneral linear modelingPatients' perceptionsMetastatic cancerPatientsSide effectsDecreased anxietyTherapyCancerCureLower ratesAnxiety Scale
2022
Trends in age and sex-specific prevalence of cancer and cancer subtypes in acute ischemic stroke from 2007-2019
Otite F, Somani S, Aneni E, Akano E, Patel S, Anikpezie N, Lamikanra O, Masoud H, Latorre J, Chaturvedi S, Mehndiratta P. Trends in age and sex-specific prevalence of cancer and cancer subtypes in acute ischemic stroke from 2007-2019. Journal Of Stroke And Cerebrovascular Diseases 2022, 31: 106818. PMID: 36323171, DOI: 10.1016/j.jstrokecerebrovasdis.2022.106818.Peer-Reviewed Original ResearchConceptsSex-specific prevalenceCancer prevalenceGenitourinary cancersAIS admissionsActive cancerGastrointestinal cancerMetastatic cancerSolid cancersPrimary central nervous system cancerRetrospective serial cross-sectional studyAcute ischemic stroke hospitalizationsSerial cross-sectional studyCentral nervous system cancerLung cancer prevalenceAcute ischemic strokeNational Inpatient SampleIschemic stroke hospitalizationsHead/neckNervous system cancersCommon solid cancersCross-sectional studyPrevalence of cancerCancer admissionsIschemic strokeStroke hospitalizationsTranscriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function
Martinek J, Lin J, Kim KI, Wang VG, Wu TC, Chiorazzi M, Boruchov H, Gulati A, Seeniraj S, Sun L, Marches F, Robson P, Rongvaux A, Flavell RA, George J, Chuang JH, Banchereau J, Palucka K. Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function. Cell Reports Medicine 2022, 3: 100621. PMID: 35584631, PMCID: PMC9133468, DOI: 10.1016/j.xcrm.2022.100621.Peer-Reviewed Original ResearchConceptsMonocytes/macrophagesDendritic cellsMetastatic melanomaMelanoma cellsMetastatic cutaneous melanomaRegulation of toleranceSpecific transcriptional signatureTranscriptional profilingGene setsLaser capture microdissectionCell-based therapiesTranscriptional signatureCutaneous melanomaDC functionPatient outcomesMetastatic cancerTumor nestsTCGA cohortImmune functionCandidate biomarkersCD14Stromal macrophagesTumor siteTherapeutic opportunitiesAntigen capturePraluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, van Oordt C, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical Cancer Research 2022, 28: 2020-2029. PMID: 35165101, PMCID: PMC9365353, DOI: 10.1158/1078-0432.ccr-21-3656.Peer-Reviewed Original ResearchConceptsAdvanced solid tumorsOpen-label phase I/II trialSolid tumorsPhase I/II trialPhase I/II clinical trialsBasis of tolerabilityPhase II doseBreast cancer subsetsAntibody-drug conjugatesProtease-cleavable linkerEligible patientsPosttreatment biopsiesPrior therapyStable diseaseII trialPartial responseSafety profileTumor regressionClinical trialsPrevalent subtypeCancer subsetsClinical activityMetastatic cancerBreast cancerMedian numberChapter 9 Vascular disorders epidemiology
Kurz S, Rogers L. Chapter 9 Vascular disorders epidemiology. 2022, 81-86. DOI: 10.1016/b978-0-12-822835-7.00060-3.Peer-Reviewed Original ResearchCancer patientsOpportunistic fungal infectionBone marrow transplantationAcute myelogenous leukemiaCerebral venous thrombosisCause of ischemic strokeAcute promyelocytic leukemiaMarrow transplantationMyelogenous leukemiaHematological tumorsVenous thrombosisMetastatic cancerFungal infectionsHealthy controlsTumor treatmentCerebral infarctionTumorAntineoplastic drugsBrain tumorsSubdural spaceRelative riskPromyelocytic leukemiaCancerIntraparenchymal haemorrhageLeukemia
2021
Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States
Parikh RB, Takvorian SU, Vader D, Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA, Investigators T. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. Journal Of The National Cancer Institute 2021, 114: 571-578. PMID: 34893865, PMCID: PMC9002283, DOI: 10.1093/jnci/djab225.Peer-Reviewed Original ResearchConceptsMetastatic solid cancersFirst-line systemic therapyTreatment initiationSolid cancersSystemic therapyTreatment patternsMyelosuppressive therapyTreatment selectionCommunity-based oncology practicesCOVID-19 pandemicTechnology-enabled abstractionDays of diagnosisLife-threatening conditionInterrupted time series analysisMetastatic diagnosisUS patientsEffect modificationOncology practiceMetastatic cancerAdjusted probabilityPatientsPandemic periodPandemic-related delaysTherapyCancer515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Lim J, Sundar R, Wong A, Yong W, Soo R, Chee C, Lee S, Goh B, Dent R, Jeraj S, Kwok L, Schiavon G, Kaliaperumal N, Foxley A, Connolly J, Tan D. 515MO A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC). Annals Of Oncology 2021, 32: s585-s586. DOI: 10.1016/j.annonc.2021.08.1037.Peer-Reviewed Original ResearchPhase I trialMetastatic cancerPan‐cancer analysis of prognostic metastatic phenotypes
Zaorsky NG, Wang X, Garrett SM, Lehrer EJ, Lin C, DeGraff DJ, Spratt DE, Trifiletti DM, Kishan AU, Showalter TN, Park HS, Yang JT, Chinchilli VM, Wang M. Pan‐cancer analysis of prognostic metastatic phenotypes. International Journal Of Cancer 2021, 150: 132-141. PMID: 34287840, PMCID: PMC8595638, DOI: 10.1002/ijc.33744.Peer-Reviewed Original ResearchConceptsLiver/lung metastasisLung metastasesOverall survivalMetastatic cancerConcordance indexCancer stage IV diseaseCox proportional hazards modelMetastatic phenotypeNational Cancer DatabaseStage IV diseaseEnd Results (SEER) databaseAmerican Joint CommitteeLong-term survivorsLatent class analysisProportional hazards modelStage IVANomogram modelResults databaseSurvival outcomesBetter prognosticationCancer DatabasePan-cancer analysisClinical trialsHazards modelJoint CommitteeRole of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancerCDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, Hodi FS, Shukla SA, Gusev A, Braun DA, Choueiri TK, Kwiatkowski DJ. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clinical Cancer Research 2021, 27: 4025-4035. PMID: 34074656, PMCID: PMC8900067, DOI: 10.1158/1078-0432.ccr-21-0575.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsUrothelial carcinomaGenomic alterationsMemorial Sloan-Kettering Cancer CenterNon-small cell lungDana-Farber Cancer InstituteICI treatment outcomesPlatinum-based therapyTumor immune microenvironmentImmuno-inflammatory pathwaysRenal cell carcinomaDFCI cohortICI therapyCheckpoint inhibitorsCancer Genome AtlasClinical benefitCancer CenterCell carcinomaCell lungPredictive biomarkersDifferent cancer typesPoor responseWorse outcomesMSK-IMPACTMetastatic cancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply